2 hours ago
Ionis Pharmaceuticals (IONS) Stock Plummets 20% Following Failed Heart Disease Trial
Ionis (IONS) stock plunged 20% after eplontersen failed its Phase 3 heart disease trial, while competitors Alnylam and BridgeBio surged on the news.
The post Ionis Pharmaceuticals (IONS) Stock Plummets 20% Following Failed Heart Disease Trial appeared first on Blockonomi.
Source: Blockonomi →Related News
- 54 minutes ago
Meta (META) Stock Surges $50 Following Neocloud Strategy Announcement
- 55 minutes ago
Lam Research (LRCX) Stock Jumps 7.5% as Analyst Upgrades Continue Rolling In
- 1 hour ago
Gold Surges Past $4,100 as Middle East Tensions and Fed Policy Uncertainty Fuel...
- 1 hour ago
Polestar (PSNY) Stock Slides 3% After Q2 Sales Decline and US Market Exit
- 1 hour ago
Micron (MU) Stock Surges 7% on Massive $250B U.S. Manufacturing Investment Plan